|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for ORM1 |
 Gene summary |
| Basic gene Info. | Gene symbol | ORM1 |
| Gene name | orosomucoid 1 | |
| Synonyms | AGP-A|AGP1|HEL-S-153w|ORM | |
| Cytomap | UCSC genome browser: 9q32 | |
| Type of gene | protein-coding | |
| RefGenes | NM_000607.2, | |
| Description | AGP 1OMD 1alpha-1-acid glycoprotein 1epididymis secretory sperm binding protein Li 153worosomucoid-1 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 138600 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000229314 | ||
| HPRD : 00724 | ||
| Vega : OTTHUMG00000021012 | ||
| Protein | UniProt: P02763 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_ORM1 | |
| BioGPS: 5004 | ||
| Pathway | NCI Pathway Interaction Database: ORM1 | |
| KEGG: ORM1 | ||
| REACTOME: ORM1 | ||
| Pathway Commons: ORM1 | ||
| Context | iHOP: ORM1 | |
| ligand binding site mutation search in PubMed: ORM1 | ||
| UCL Cancer Institute: ORM1 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for ORM1 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | I106 | G104R | SKCM | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for ORM1 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | I106 | G104R | -0.14700417 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for ORM1 from PDB |
| Top |
| Differential gene expression and gene-gene network for ORM1 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for ORM1 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0085605 | Liver Failure | 1 | Therapeutic |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for ORM1 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Approved|vet_approved | DB00477 | Chlorpromazine | Small molecule |  |
| Approved|illicit|investigational | DB00497 | Oxycodone | Small molecule |  |
| Approved|investigational|withdrawn | DB01041 | Thalidomide | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of ORM1 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of ORM1 |
| Multiple alignments for P02763 in multiple species |
| LBS | AA sequence | # species | Species | F132 | TYMLAFDVNDE | 1 | Homo sapiens | F132 | TFMLAFNLTDE | 1 | Rattus norvegicus | F132 | TFMLAASWNGT | 1 | Bos taurus | F67 | IQATFFYFTPN | 1 | Homo sapiens | F67 | IQTEYFYLTPN | 1 | Rattus norvegicus | F67 | IQAAFFYLEPR | 1 | Bos taurus | I106 | RENGTISRYVG | 1 | Homo sapiens | I106 | RENGTLSKCAG | 1 | Rattus norvegicus | I106 | RQNGTLSKVES | 1 | Bos taurus | L130 | TKTYMLAFDVN | 1 | Homo sapiens | L130 | HGTFMLAFNLT | 1 | Rattus norvegicus | L130 | FRTFMLAASWN | 1 | Bos taurus | R108 | NGTISRYVGGQ | 1 | Homo sapiens | R108 | NGTLSKCAGAV | 1 | Rattus norvegicus | R108 | NGTLSKVESDR | 1 | Bos taurus | S107 | ENGTISRYVGG | 1 | Homo sapiens | S107 | ENGTLSKCAGA | 1 | Rattus norvegicus | S107 | QNGTLSKVESD | 1 | Bos taurus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |